Thursday, July 9, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Dogwood Pharmaceuticals, Inc.”

7 pharma patents match "Dogwood Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 7
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 7 pharmaceutical patents matching "Dogwood Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

7 results for “Dogwood Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9446021

    Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

    Dogwood Pharmaceuticals, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted
  2. US 9120754

    Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

    Dogwood Pharmaceuticals, Inc. · Granted Sep 1, 2015 · Expires Aug 27, 2035

    granted
  3. US 8349848

    Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors

    Dogwood Pharmaceuticals, Inc. · Granted Jan 8, 2013 · Expires Jan 3, 2033

    granted
  4. US 8293720

    Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

    Dogwood Pharmaceuticals, Inc. · Granted Oct 23, 2012 · Expires Oct 18, 2032

    granted
  5. US 8263762

    Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists

    Dogwood Pharmaceuticals, Inc. · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  6. US 8258142

    Substituted 8-[6-amino-3-pyridyl]xanthines

    Dogwood Pharmaceuticals, Inc. · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  7. US 8252767

    Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

    Dogwood Pharmaceuticals, Inc. · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted